Form 4: Tango Therapeutics Director Mace Rothenberg Reports Significant Equity Awards

Tango Therapeutics Director Mace Rothenberg has reported the acquisition of 6,250 restricted stock units and 37,500 stock options, signaling new equity compensation.

Summary

• Mace Rothenberg, a Director of Tango Therapeutics, Inc. (TNGX), reported new equity awards on June 5, 2025.
• He acquired 6,250 shares of Common Stock in the form of Restricted Stock Units (RSUs) at a price of $0.
• These RSUs are set to vest in their entirety on the earlier of June 5, 2026, or the date of the next annual meeting of stockholders, contingent on his continuous service.
• Additionally, Mr. Rothenberg acquired 37,500 stock options with an exercise price of $3.51 per share and an expiration date of June 5, 2035.
• These stock options will vest in 12 substantially equal monthly installments over a period of one year, with the first vesting date on July 5, 2025, also subject to his continuous service.
• Following these transactions, Mr. Rothenberg directly beneficially owns 37,500 shares of Common Stock and 37,500 stock options.

Sentiment

Score: 7

Explanation: The grant of restricted stock units and stock options to a director is generally a positive signal as it aligns management's interests with long-term shareholder value, incentivizing performance and retention. It is a routine compensation event rather than a direct investment or sale.

Positives

• The grant of new equity awards (Restricted Stock Units and stock options) to a director aligns their interests with those of shareholders, incentivizing long-term performance.
• The acquisition of stock options with a strike price of $3.51 suggests a belief in the company's potential for future stock price appreciation above this level.

Risks

• The vesting of both the Restricted Stock Units and stock options is contingent upon the Reporting Person's continuous service with Tango Therapeutics, Inc., meaning the awards could be forfeited if service terminates before vesting.

Future Outlook

The document outlines future equity compensation realization through vesting schedules. The 6,250 Restricted Stock Units are expected to vest by June 5, 2026, or the next annual meeting, and the 37,500 stock options will vest monthly over one year starting July 5, 2025, all contingent on continuous service.

Industry Context

This Form 4 filing represents a routine disclosure of insider equity compensation, a common practice across industries, particularly in biotechnology, to incentivize and retain key personnel by aligning their financial interests with the company's long-term performance.

Stakeholder Impact

• Shareholders: The equity awards align the director's financial interests with shareholder value, potentially leading to improved long-term company performance.
• Employees: The use of equity compensation for a director reinforces the company's overall incentive structure, which can positively influence employee morale and retention strategies.

Next Steps

• Vesting of 6,250 Restricted Stock Units (RSUs) on the earlier of June 5, 2026, or the date of the next annual meeting of stockholders, subject to continuous service.
• Monthly vesting of 37,500 stock options over a one-year period, commencing July 5, 2025, subject to continuous service.

Key Dates

Recommendation

Keywords

Tango Therapeutics, TNGX, Form 4, Insider Transaction, Equity Compensation, Restricted Stock Units, Stock Options, Director Compensation, Beneficial Ownership